Five things to prepare before a USFDA submission

There is a persistent myth that submission readiness begins when the last patient completes their final visit. In practice, the programs that clear regulatory review most smoothly are the ones where every downstream deliverable was anticipated at protocol design — where the study was, in a real sense, built backwards from the filing. By the time database lock arrives, the question of whether a submission will be defensible has largely already been answered. What follows is an outline of five things that, in our experience, most determine how a USFDA submission is received.

First, the statistical analysis plan must be finalised before database lock — not drafted, not mostly agreed, but locked. The credibility of a study's conclusions rests on the principle that the analysis was specified before anyone could see how the data would respond to it. A SAP that is still being edited as unblinded data comes into view invites exactly the suspicion regulators are trained to have: that analytical choices were shaped, consciously or not, by the results they produce. A finalised SAP, with pre-specified primary and secondary endpoints, handling of missing data, and sensitivity analyses, is the single clearest signal that a study was run with integrity.

Second, source data must reconcile cleanly to the clinical study report. Reviewers do not take the CSR on trust; they trace its numbers back through the datasets to the source. Every discrepancy between what a site recorded, what the database holds, and what the report states is a thread a reviewer can pull — and each one costs time and credibility. A disciplined data management process, with a clear audit trail from source to summary, means that when a reviewer traces a figure they find that it reconciles. That experience, repeated, is what builds a reviewer's confidence in the entire submission.

Third, the monitoring trail must be documented and defensible. It is not enough for a study to have been well monitored; the file must demonstrate it. That means monitoring visit reports, evidence of issue escalation and resolution, and — for studies run under risk-based monitoring — clear documentation of the risk assessment, the quality tolerance limits, and the actions taken when signals arose. A submission that can show not only clean data but a coherent, contemporaneous record of how that cleanliness was assured is in a materially stronger position than one that simply asserts quality.

Fourth, bioanalytical method validation must meet regulated-market standards. For studies with a pharmacokinetic or bioequivalence component, the quality of the underlying assay is not a technical footnote — it is foundational. Method validation covering accuracy, precision, selectivity, sensitivity, stability and reproducibility, documented to FDA bioanalytical method validation expectations, is what allows the concentration data to be relied upon at all. Deficiencies here are particularly damaging because they can call into question not one analysis but the entire quantitative basis of the study.

Fifth, patient narratives must be authored to ICH E3. For every death, every serious adverse event, and every discontinuation due to an adverse event, reviewers expect a clear, consistent narrative that tells the clinical story: the patient's relevant history, the event, its timing and management, and its outcome. Narratives that are complete, internally consistent, and consistent with the underlying data allow a reviewer to understand the safety profile quickly. Narratives that are thin, contradictory, or misaligned with the datasets force the reviewer to reconstruct the story themselves — and invite questions.

What unites these five is a single principle: nothing on the list can be manufactured after the fact. A SAP cannot be retroactively locked; a clean reconciliation cannot be assembled from a messy trail; a monitoring record cannot be back-filled; an assay cannot be re-validated on data already generated; and honest narratives cannot be written from incomplete source. Each is the product of decisions made early and executed consistently across the life of the study.

Getting these right does not merely avoid problems — it changes the character of the submission itself. When the analysis was pre-specified, the data reconciles, the monitoring is documented, the bioanalysis is sound and the narratives are clean, the filing stops being a defensive exercise and becomes a straightforward account of a well-run study. That is what shortens the path from database lock to approval: not luck at review, but rigour long before it.